Payment overview · 2025
General Payments
$321.06
15 reported records · 9 companies
Healthcare provider profile · identity verified
Thomas Eugene Browning, P.A. C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FORT WORTH, TX · NPI 1770617060
Verified facts
What the public records show
CMS Open Payments records show Thomas Eugene Browning, P.A. C received $321.06 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $90.84 | 28.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $42.01 | 13.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.80 | 13.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $35.44 | 11.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.88 | 8.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.22 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.94 | 7.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.15 | 6.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.78 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.06 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $42.01 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.80 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $25.22 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 45 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 574 | 195 |
| Levothyroxine Sodium | Levothyroxine Sodium | 504 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 150 |
| Lisinopril | Lisinopril | 343 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 114 |
| Metformin Hcl | Metformin Hcl | 299 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 285 | 94 |
| Losartan Potassium | Losartan Potassium | 252 | 86 |
| Alprazolam | Alprazolam | 249 | 51 |
| Furosemide | Furosemide | 224 | 82 |
| Potassium Chloride | Potassium Chloride | 222 | 83 |
| Trazodone Hcl | Trazodone Hcl | 203 | 79 |
| Tramadol Hcl | Tramadol Hcl | 199 | 66 |
| Gabapentin | Gabapentin | 198 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 187 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 184 | 58 |
| Omeprazole | Omeprazole | 175 | 56 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 60 |
| Montelukast Sodium | Montelukast Sodium | 150 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 51 |
| Prednisone | Prednisone | 146 | 97 |
| Cefdinir | Cefdinir | 138 | 121 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 48 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 125 | 35 |
| Allopurinol | Allopurinol | 101 | 30 |
| Meloxicam | Meloxicam | 100 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 33 |
| Glimepiride | Glimepiride | 93 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 91 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 29 |
| Lorazepam | Lorazepam | 87 | 18 |
| Carvedilol | Carvedilol | 86 | 34 |
| Atenolol | Atenolol | 85 | 27 |
| Azithromycin | Azithromycin | 85 | 63 |
| Clonazepam | Clonazepam | 79 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 78 | 61 |
| Eliquis | Apixaban | 76 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 24 |
| Simvastatin | Simvastatin | 74 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 29 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 62 | suppressed |
| Estradiol | Estradiol | 61 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 29 |
| Donepezil Hcl | Donepezil Hcl | 58 | 15 |
| Buspirone Hcl | Buspirone Hcl | 53 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 50 | 16 |
| Cephalexin | Cephalexin | 48 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 26 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 47 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 14 |
| Ozempic | Semaglutide | 45 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Finasteride | Finasteride | 43 | 14 |
| Aripiprazole | Aripiprazole | 40 | 11 |
| Glipizide | Glipizide | 40 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Celecoxib | Celecoxib | 38 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | 11 |
| Sulindac | Sulindac | 36 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 15 |
| Clonidine Hcl | Clonidine Hcl | 35 | 16 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | 12 |
| Jardiance | Empagliflozin | 30 | 14 |
| Promethazine Hcl | Promethazine Hcl | 30 | 14 |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | 12 |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Sertraline Hcl | Sertraline Hcl | 28 | 14 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 26 |
| Mupirocin | Mupirocin | 25 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 25 | suppressed |
| Ramipril | Ramipril | 25 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 24 | 14 |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | 15 |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 22 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 11 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Glipizide Er | Glipizide | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 14 |
| Baclofen | Baclofen | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Lactulose | Lactulose | 16 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.06 · 15 records | Novo Nordisk Inc | ABRYSVO, Auvelity, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FREESTYLE LIBRE, MOUNJARO, Ozempic, PREVNAR 20, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error